Abstract
Pulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive evidence, expert consensus can supply clinically useful guidance in medicine. An international panel of 26 experts participated in a Delphi process to identify consensus on pharmacological management in sarcoidosis with the development of preliminary recommendations.The modified Delphi process used three rounds. The first round focused on qualitative data collection with open-ended questions to ensure comprehensive inclusion of expert concepts. Rounds 2 and 3 applied quantitative assessments using an 11-point Likert scale to identify consensus.Key consensus points included glucocorticoids as initial therapy for most patients, with non-biologics (immunomodulators), usually methotrexate, considered in severe or extrapulmonary disease requiring prolonged treatment, or as a steroid-sparing intervention in cases with high risk of steroid toxicity. Biologic therapies might be considered as additive therapy if non-biologics are insufficiently effective or are not tolerated with initial biologic therapy, usually with a tumour necrosis factor-α inhibitor, typically infliximab.The Delphi methodology provided a platform to gain potentially valuable insight and interim guidance while awaiting evidenced-based contributions.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Anti-inflammatory Therapy for Sarcoidosis;Clinics in Chest Medicine;2024-03
2. Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis;Journal of Clinical Medicine;2024-01-27
3. Anti-Granulomatous Therapy for Pulmonary Sarcoidosis;Sarcoidosis - Diagnosis, Research, and Therapy of a Granulomatous Disease of Unknown Etiology - To remind what we already knew and learn something new about this disease [Working Title];2024-01-06
4. Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis;Journal of Clinical Medicine;2023-12-31
5. Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action;Journal of Clinical Medicine;2023-12-19